

REMARKS

Changes have been made to the specification on page 5 to insert proper sequence identifiers. The specification is further corrected and a substitute Sequence Listing is herein submitted to comply with the requirements of an application containing a nucleotide and/or amino acid sequence 37 C.F.R. §§ 1.821 - 1.825.

Hereto is an attached substitute Sequence Listing in paper and computer readable format. The paper copy and computer readable copy of the substitute Sequence Listing are the same. The substitute Sequence Listing submitted herein is the same as that submitted on March 18, 2004, except that the attorney reference no. <130> has been amended from "0641-0028" to "064162-0028". The substitute Sequence Listing does not include new matter.

CONCLUSION

Entry of the substitute Sequence Listing, corrections to the specification and favorable consideration are respectfully requested.

To the extent necessary, please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees, to Deposit Account 500417.

Respectfully submitted,
McDERMOTT, WILL & EMERY LLP

Date: 6/23/04

By: Kelli N. Watson
Kelli N. Watson
Registration No. 47,170

600 Thirteenth Street, N.W.
Washington, D.C. 20005-3096
(202) 756-8351 (Direct)
(202) 756-8087 (Facsimile)

WDC99 930993-1.064162.0028